Loading…
← CockpitCompetitor Analysis › 688068.SS Beijing Hotgen Biotech Co. Ltd. Class AOpen in the cockpit ↗

Beijing Hotgen Biotech Co. Ltd. Class A688068.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese molecular and rapid-diagnostics maker selling PCR and antigen test kits for infectious diseases.

≈ A Chinese Cepheid/Abbott Rapid Diagnostics for infectious-disease testsMomentum laggard 5
Mkt cap
$815M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$21.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-27.1 pp
WACC 8.8%
Hurdle
n/a
no reverse DCF
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥59.64
1D-3.3%
1W-16.5%
1M-20.8%
3M-48.1%
6M-37.5%
YTD-63.2%
1Y-57.6%
ATR %7.3%
52w lowhigh72.2% off high

What Beijing Hotgen Biotech does

Chinese molecular and rapid-diagnostics maker selling PCR and antigen test kits for infectious diseases.

Sells test kits and the instruments that run them, so each installed analyser brings repeat kit orders. Covid testing lifted sales sharply in the early 2020s, and the business has since returned to routine infectious-disease testing and export orders.

In one line: A Chinese Cepheid/Abbott Rapid Diagnostics for infectious-disease tests.

Products and services

  • PCR diagnostic reagents
  • Rapid antigen test kits
  • POCT diagnostic instruments

Customers

  • Hospital/CDC laboratories
  • Public health agencies
  • Export markets

Where it sits in the supply chain

  • Health Care
  • In-vitro diagnostics
  • Molecular & rapid antigen diagnostic…

What could go right

  • Infectious-disease testing demand
  • Export market expansion

What could go wrong

  • Post-pandemic testing demand normalization

Moat: narrow (regulatory licence, installed base). Disease-testing registrations and installed instrument base favor an incumbent supplier.

Headquarters: Beijing, China · Employees: 946

Named competitors

Beijing Hotgen Biotech at a glance

Size Beijing Hotgen Biotech (688068.SS) is a China Health Care company (Medical Specialties) with a market value of $815M, the 2552nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥59.64 on 18 Nov 2026.

Performance Over six months the shares fell 37.5%, against -12.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 8.2% over the last twelve months (peer median +6.2%); the operating margin is -94.3% (peer median 10.2%).

Valuation It trades at 9.6× enterprise value to sales against a peer median of 3.5× (4th most expensive of 21).

Capital Return on invested capital runs 27.1 points below its cost of capital (8.8% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026Peer median 88688068.SS 64
Six months, rebased to 100: Beijing Hotgen Biotech against the median of its 20 peers (local-currency closes).

Beijing Hotgen Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥470MCN¥404MCN¥508MCN¥546MCN¥3.55B
Revenue growth—-20%-7%-85%—
Gross profitCN¥311MCN¥157MCN¥193MCN¥262MCN¥1.84B
EBITDAn/a-CN¥189M-CN¥111MCN¥25.6MCN¥1.25B
Net income-CN¥316M-CN¥216M-CN¥206MCN¥28.9MCN¥945M
Free cash flow-CN¥339M-CN¥92.8M-CN¥104M-CN¥435MCN¥431M
Capital expenditureCN¥111MCN¥43.6MCN¥52.8MCN¥413MCN¥565M
Total debtCN¥28.6MCN¥75.7MCN¥85.4MCN¥16.1MCN¥42.1M

Quarterly statements and history in the cockpit →

Beijing Hotgen Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%-10%0%+10%688805MCAPAMS096530KIDS11876033673600SETLBBNXMLABCTKB3016026886561302VREX0026582190688277688626688068.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Hotgen Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×5×10×688805MCAPAMS096530KIDS11876033673600SETLBBNXMLABCTKB3016026886561302VREX0026582190688277688626688068.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Hotgen Biotech is the large dot.

Beijing Hotgen Biotech competitors and peer comparison

Head to head with its named competitors (688068.SS vs 688289.SS vs DHR vs ABT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Beijing Hotgen Biotech 688068.SS$815M-37%+8%-94%9.6×n/a
Sansure Biotech 688289.SS$1.24B-17%-1%1%3.8×n/a
Danaher DHR$161B+34%+6%21%7.1×20.8%
Abbott Laboratories ABT$181B+18%+10%14%4.3×16.5%

How Beijing Hotgen Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Hotgen Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688068.SSPeer medianRank in peer set
1-month return-20.8%-4.8%2nd lowest of 21
6-month return-37.5%-12.6%2nd lowest of 21
Distance from 52-week high-72.2%-37.6%lowest of 21
Revenue growth (TTM)+8.2%+6.2%10th highest of 21
Operating margin-94.3%10.2%lowest of 21
EV / Sales9.6×3.5×4th most expensive of 21
ROIC minus cost of capital-27.1 pp-1.3 pp3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%9.6×n/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%6.8×35.6%+17.1%
MedCap MCAP.STSweden$811M-4%+17%15%3.6×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%3.0×20.0%+21.4%
Seegene 096530.KSSouth Korea$808M-26%+13%13%1.2×-6.7%-15.9%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%3.4×n/an/a
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%1.0×-6.4%+6.6%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%0.7×-14.6%-1.3%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%1.6×-7.1%+11.3%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%7.7×n/an/a
Beta Bionics BBNXUnited States$779M+42%+44%-73%4.3×n/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%3.6×21.3%+13.2%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%2.6×n/an/a
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%12.0×11.1%+4.6%
HOB Biotech 688656.SSChina$858M-33%+6%7%13.7×37.6%+12.4%
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%3.2×9.6%+15.5%
Varex Imaging VREXUnited States$771M+79%+5%8%1.2×n/an/a
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%3.3×16.8%+2.9%
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%3.6×3.8%+105.8%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%21.7×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%7.2×n/an/a

Questions

Who are Beijing Hotgen Biotech's main competitors?
Named competitors: Sansure Biotech (688289.SS), Cepheid (Danaher) (DHR), Abbott Rapid Diagnostics (ABT). The cockpit's measured peer set (industry) also includes Ningbo Jansen Superconducting Technologies (688805.SS), MedCap (MCAP.ST), Advanced Medical Solutions (AMS.L), Seegene (096530.KS), OrthoPediatrics (KIDS), Cofoe Medical Technology (1187.HK).
Is Beijing Hotgen Biotech expensive compared with its peers?
On ev / sales it trades at 9.6× against a peer median of 3.5×, 4th most expensive of 21 in its peer set.
How has Beijing Hotgen Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -37.5% against -12.6% for the median peer; over one year -57.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.